Vol. 30-31/2021-2022 Nr 60
okładka czasopisma Child Neurology
powiększenie okładki
Informacje o Pismie

NEUROLOGIA DZIECIĘCA

Pismo Polskiego Towarzystwa Neurologów Dziecięcych

PL ISSN 1230-3690
e-ISSN 2451-1897
DOI 10.20966
Półrocznik


Powrót

Zastosowanie okskarbazepiny w leczeniu padaczki u dzieci poniżej 6 roku życia – przegląd piśmiennictwa


The use of oxcarbazepine in treatment of epilepsy in children younger than 6 years – literature review




Klinika Neurologii Rozwojowej, Katedra Neurologii, Gdański Uniwersytet Medyczny

Neurol Dziec 2011; 20, 40: 47-51
Pełen tekst artykułu PDF Zastosowanie okskarbazepiny w leczeniu padaczki u dzieci poniżej 6 roku
życia – przegląd p



STRESZCZENIE
Okskarbazepina (OXC) jest lekiem przeciwpadaczkowym nowej generacji, zarejestrowanym w Polsce w leczeniu napadów częściowych, również tych wtórnie uogólnionych, w terapii dodanej i monoterapii, u dorosłych i dzieci powyżej 6 roku życia. W USA lek jest zarejestrowany do leczenia napadów częściowych w monoterapii u dorosłych i dzieci powyżej 4 roku życia, w terapii dodanej powyżej 2 roku życia. W przedstawionej pracy przedstawiono dane z piśmiennictwa dotyczące skuteczności oraz występowania objawów niepożądanych podczas terapii OXC w grupach najmłodszych dzieci. Wyniki przeprowadzonych badań zarówno tych randomizowanych jak i nierandomizowanych, otwartych prospektywnych i długoterminowych wykazano, że OXC u znacznego odsetka pacjentów prowadzi do uwolnienia od napadów zwłaszcza gdy jest zastosowana jako lek w monoterapii w nowozdiagnozowanej padaczce, jej efekt działania jest również zadawalający w przypadkach padaczek trudno poddających się leczeniu. Istotne jest, że lek ten może stanowić wartościową opcję terapeutyczną w najmłodszych grupach wiekowych również dzięki niewielkiej tendencji do wywoływania objawów niepożądanych.

Słowa kluczowe: okskarbazepina, padaczka, dzieci


ABSTRACT
Oxcarbazepine (OXC) the new generation antiepileptic drug is register in Poland in treatment of partial and secondarily generalized seizures as add-on or monotherapy in adults and children above 6 years of age. In United States OXC is registered for use as a monotherapy in patients older than 4 years and as add-on therapy in patients above second year of age. Present work shows the avaible literature concerning the efficacy and safety of OXC when used in the younger age children. The data based on randomized as well as nonrandomized, open label, prospective and long term trials shows acceptable efficacy when used in monotherapy in newly diagnosed epilepsy and also as add on therapy in drug-resistant epilepsies in children. It is important to notice that OXC is a valuable therapeutic option in the younger age groups also because of small potential to cause side-effects.

Key words: oxcarbazepine, epilepsy, children


PIŚMIENNICTWO
[1] 
McLean M.J., Schmutz M., Wamil A.W., et al.: Oxcarbazepine: mechanisms of action. Epilepsia, 1994;35:5-9.
[1] 
McLean M.J., Schmutz M., Wamil A.W., et al.: Oxcarbazepine: mechanisms of action. Epilepsia, 1994;35:5-9.
[2] 
Patsalos P.N., Elyas A.A., Zakrzewska J.M.: Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol, 1990;39: 413-415.
[2] 
Patsalos P.N., Elyas A.A., Zakrzewska J.M.: Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol, 1990;39: 413-415.
[3] 
Flesch G.: Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig, 2004;24:185-203.
[3] 
Flesch G.: Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig, 2004;24:185-203.
[4] 
Gonzalez-Esquivel D.F., Ortega-Gavilan M., Alcantara-Lopez G., et al.: Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res, 2000;31:202-205.
[4] 
Gonzalez-Esquivel D.F., Ortega-Gavilan M., Alcantara-Lopez G., et al.: Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res, 2000;31:202-205.
[5] 
Keranen T., Jolkkonen J., Jensen P.K., et al.: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand, 1992; 86:120-123.
[5] 
Keranen T., Jolkkonen J., Jensen P.K., et al.: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand, 1992; 86:120-123.
[6] 
Keranen T., Jolkkonen J., Klosterskov-Jensen P., et al.: Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand, 199;85:239-242.
[6] 
Keranen T., Jolkkonen J., Klosterskov-Jensen P., et al.: Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand, 199;85:239-242.
[7] 
Adin J., Arteaga R., Herranz J.L., et al.: The use of intravenous valproate. Rev Neurol, 1999;29:744-753.
[7] 
Adin J., Arteaga R., Herranz J.L., et al.: The use of intravenous valproate. Rev Neurol, 1999;29:744-753.
[8] 
Baruzzi A., Albani F., Riva R.: Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia, 1994;35:14-19.
[8] 
Baruzzi A., Albani F., Riva R.: Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia, 1994;35:14-19.
[9] 
Sallas W.M., Milosavljev S., D’Souza J., et al.: Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther, 2003; 74:138-149.
[9] 
Sallas W.M., Milosavljev S., D’Souza J., et al.: Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther, 2003; 74:138-149.
[10] 
Reinikainen K.J., Keranen T., Halonen T., et al.: Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res, 1987;1:284-289.
[10] 
Reinikainen K.J., Keranen T., Halonen T., et al.: Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res, 1987;1:284-289.
[11] 
Glauser T.A.: Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy, 2001;21:904-919
[11] 
Glauser T.A.: Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy, 2001;21:904-919
[12] 
Barcs G., Walker E.B., Elger C.E., et al.: Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia, 2000;41:1597-1607.
[12] 
Barcs G., Walker E.B., Elger C.E., et al.: Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia, 2000;41:1597-1607.
[13] 
Glauser T.A., Nigro M., Sachdeo R., et al.: Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology, 2000;54:2237-2244.
[13] 
Glauser T.A., Nigro M., Sachdeo R., et al.: Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology, 2000;54:2237-2244.
[14] 
Pina-Garza J.E., Espinoza R., Nordli D.: Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology, 2005;65; 1370-1375.
[14] 
Pina-Garza J.E., Espinoza R., Nordli D.: Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology, 2005;65; 1370-1375.
[15] 
Dam M., Ekberg R., Loyning Y., et al.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res, 1989;3:70-76.
[15] 
Dam M., Ekberg R., Loyning Y., et al.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res, 1989;3:70-76.
[16] 
Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res, 1997;27:195-204.
[16] 
Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res, 1997;27:195-204.
[17] 
Guerreiro M.M., Vigonius U., Pohlmann H., et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res, 1997;27:205-213.
[17] 
Guerreiro M.M., Vigonius U., Pohlmann H., et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res, 1997;27:205-213.
[18] 
Christe W., Kramer G., Vigonius U., et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res, 1997;26:451-460.
[18] 
Christe W., Kramer G., Vigonius U., et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res, 1997;26:451-460.
[19] 
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol, 1997;12:496-498.
[19] 
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol, 1997;12:496-498.
[20] 
Korn-Merker E., Holtmann M. Krause M.: Oxcarbazepine: experiences in 142children and adolescents with difficult-to-treat epilepsies [abstract]. Epilepsia, 2001;42 (Suppl 7): 181.
[20] 
Korn-Merker E., Holtmann M. Krause M.: Oxcarbazepine: experiences in 142children and adolescents with difficult-to-treat epilepsies [abstract]. Epilepsia, 2001;42 (Suppl 7): 181.
[21] 
Mandelbaum D., Kugler S.: Efficacy of oxcarbazepine in the treatment of children with partial seizures [abstract]. Epilepsia, 2000;41(Suppl 7): 185-186.
[21] 
Mandelbaum D., Kugler S.: Efficacy of oxcarbazepine in the treatment of children with partial seizures [abstract]. Epilepsia, 2000;41(Suppl 7): 185-186.
[22] 
Kothare S.V., Mohsem B., Melvin J.J., et al.: Oxcarbazepine monothapy in children and adolescents: a single-center clinical experience. Pediatr Neurol, 2006;35:235-239.
[22] 
Kothare S.V., Mohsem B., Melvin J.J., et al.: Oxcarbazepine monothapy in children and adolescents: a single-center clinical experience. Pediatr Neurol, 2006;35:235-239.
[23] 
Kothare S.V., Mostofi N., Khurana D.S., et al.: Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neurol, 2006;35:173-176.
[23] 
Kothare S.V., Mostofi N., Khurana D.S., et al.: Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neurol, 2006;35:173-176.
[24] 
Coppola G., Franzoni E., Verrotti A., et al.: Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev, 2007;29:281-284.
[24] 
Coppola G., Franzoni E., Verrotti A., et al.: Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev, 2007;29:281-284.
[25] 
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intell. Disability Research 199;42:41-45.
[25] 
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intell. Disability Research 199;42:41-45.
[26] 
Franzoni E., Garone C., Sarajlija J., et al.: Open prospective study on oxcarbazepine in epilepsy in children: A preliminary report, Seizure; 2006;15:292-298.
[26] 
Franzoni E., Garone C., Sarajlija J., et al.: Open prospective study on oxcarbazepine in epilepsy in children: A preliminary report, Seizure; 2006;15:292-298.
[27] 
Franzoni E.: Prospective study on treatment of oxcarbazepine in pediatric epilepsy. J. Neurol, 2009;256:1527-1532.
[27] 
Franzoni E.: Prospective study on treatment of oxcarbazepine in pediatric epilepsy. J. Neurol, 2009;256:1527-1532.
[28] 
Ferraro D., Daraio S., Solis P.: Oxcarbazepine in early childhood [abstract]. Epilepsia, 1997;38(Suppl 8):96.
[28] 
Ferraro D., Daraio S., Solis P.: Oxcarbazepine in early childhood [abstract]. Epilepsia, 1997;38(Suppl 8):96.
[29] 
Jędrzejczak J., Zwoliński, P.: [Red.]. Nowe leki przeciwpadaczkowe. 2000, Fundacja Epileptologii: Warszawa.
[29] 
Jędrzejczak J., Zwoliński, P.: [Red.]. Nowe leki przeciwpadaczkowe. 2000, Fundacja Epileptologii: Warszawa.
[30] 
Dong X., Leppik I.E., White J., et al.: Hyponatremia from oxcarbazepine and carbamazepine. Neurology, 2005;65:1976-1978.
[30] 
Dong X., Leppik I.E., White J., et al.: Hyponatremia from oxcarbazepine and carbamazepine. Neurology, 2005;65:1976-1978.
[31] 
Van Amelsvoort T., Bakshi R., Devaux C.B., et al.: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia, 1994;35:181-188.
[31] 
Van Amelsvoort T., Bakshi R., Devaux C.B., et al.: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia, 1994;35:181-188.
[32] 
Aikia M., Kalviainen R., Sivenius J., et al.: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res, 1992;11:199-203.
[32] 
Aikia M., Kalviainen R., Sivenius J., et al.: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res, 1992;11:199-203.
[33] 
Mazurkiewicz-Bełdzińska M., Olszewska A.: Wpływ karbamazepiny, fenytiony i okskarbazepiny na funkcje poznawcze u dzieci z padaczką. Epileptologia, 2000;8:35-46.
[33] 
Mazurkiewicz-Bełdzińska M., Olszewska A.: Wpływ karbamazepiny, fenytiony i okskarbazepiny na funkcje poznawcze u dzieci z padaczką. Epileptologia, 2000;8:35-46.
[34] 
Northam R.S., Hernandez A.W., Litzinger M.J., et al.: Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol, 2005; 33:337-344.
[34] 
Northam R.S., Hernandez A.W., Litzinger M.J., et al.: Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol, 2005; 33:337-344.
[35] 
Schmidt D., Arroyo S., Baulac M., et al.: Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand, 2001;104:167-170.
[35] 
Schmidt D., Arroyo S., Baulac M., et al.: Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand, 2001;104:167-170.
[36] 
Seneviratne U., D’Souza W., Cook M.: Long-term assessment of oxcarbazepine in a naturalistic setting: a retrospective study. Acta Neurol Scand, 2008;117:367-369.
[36] 
Seneviratne U., D’Souza W., Cook M.: Long-term assessment of oxcarbazepine in a naturalistic setting: a retrospective study. Acta Neurol Scand, 2008;117:367-369.
Powrót
 

Najczęsciej pobierane
Semiologiczna i psychiatryczna charakterystyka dzieci z psychogennymi napadami rzekomopadaczkowymi
Neurol Dziec 2018; 27, 55: 11-14
Autyzm dziecięcy – współczesne spojrzenie
Neurol Dziec 2010; 19, 38: 75-78
Obraz bólów głowy w literaturze pięknej i poezji na podstawie wybranych utworów
Neurol Dziec 2016; 25, 50: 9-17

Narzędzia artykułu
Manager cytowań
Format:

Scholar Google
Artykuły aut.:Mazurkiewicz-Bełdzińska M

PubMed
Artykuły aut.:Mazurkiewicz-Bełdzińska M


Copyright © 2017 by Polskie Towarzystwo Neurologów Dziecięcych